Stories
Top highlights include: Changes to outpatient visitor restrictions in Rochester, MN, Mayo Clinic Q&A podcast on the COVID-19 delta variant, and respiratory illnesses on the rise with symptoms similar to COVID-19.
Mayo Clinic renal pathologist Dr. Sanjeev Sethi identified NELL-1 as a biomarker for membranous nephropathy (MN) in 2019. Two years later, Dr. Sethi helped implement the first ever IHC test to detect NELL-1 antigen, which appears in about 10% of MN patients and is linked to underlying malignancy.
This week’s research roundup features a study on acute treatments for episodic migraine in adults: A systematic review and meta-analysis.
Topic includes: new vaccine platform invented by Mayo enters COVID-19 clinical trial, Q&A on vaccination and precautions and the new work-life balancing act.
Mayo Clinic’s Advanced Diagnostics Laboratory (ADL) is a visionary space designed to foster innovation. The ADL has a direct impact on patient lives, bringing promising tests and services to patients at Mayo and around the world.
Shawn Mitchell brings a wealth of laboratory expertise to his role as a senior product manager at Mayo Clinic Laboratories, where he puts his knowledge to work promoting Mayo’s innovative infectious disease testing.
This week’s research roundup features a study on how ciliopathy protein HYLS1 coordinates the biogenesis and signaling of primary cilia by activating the ciliary lipid kinase PIPKIγ.
This week’s research roundup features a study on MAP3K7-IKK inflammatory signaling modulates AR protein degradation and prostate cancer progression.
This week’s research roundup features a study on acute treatments for episodic migraine in adults: A systematic review and meta-analysis.
Top stories include: COVID-19 travel tips for people with weakened immune systems, Mayo clinic Q&A on examining reports of heart inflammation in young people after second COVID-19 vaccine, and what Mayo Clinic has to offer with COVID-19 walk in vaccine clinics in Minnesota.
Delta Health leveraged their relationship with Mayo Clinic Laboratories to support patient in rural Colorado during the COVID-19 pandemic. Delta Health and Mayo Clinic Laboratories have collaborated for over 17 years to perform complex and esoteric testing.
In her role as a laboratory technologist resource coordinator, Amy Nelson has to be prepared to handle whatever questions, concerns or issues come her way from Mayo Clinic Laboratories' clients. That ability to be ready for anything has served her well as her work has shifted and changed during the COVID-19 pandemic.
For patients with chronic lymphocytic leukemia (CLL) — the most common leukemia in adults — advanced testing can not only provide valuable information about their disease state, but peace of mind in the face of a progressive, incurable illness. Oftentimes, however, complex molecular and genetic tests to identify biomarker cues about disease trajectory and treatment intolerance are not performed, putting patients at risk for unmet expectations and unsatisfactory outcomes.